Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT	300 treatment-resistant people	Proportion of people with clinically significant high levels of prolactin 6 weeks 6/135 (4%) with aripiprazole 79/137 (58%) with perphenazine	P <0.001	Effect size not calculated	aripiprazole
RCT	300 treatment-resistant people	Proportion of people with extrapyramidal symptoms 21/153 (14%) with aripiprazole 28/144 (19%) with perphenazine	Significance not assessed
RCT	300 treatment-resistant people	Proportion of people with insomnia 37/153 (24%) with aripiprazole 30/144 (21%) with perphenazine	Significance not assessed